WallStSmart

Applied Therapeutics Inc (APLT)vsBeiGene, Ltd. (ONC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BeiGene, Ltd. generates 612796% more annual revenue ($6.13B vs $1.00M). ONC leads profitability with a 10.7% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 64/100 (C+).

APLT

Avoid

27

out of 100

Grade: F

Growth: 6.3Profit: 2.5Value: 6.7Quality: 4.5
Piotroski: 3/9Altman Z: -11.31

ONC

Buy

64

out of 100

Grade: C+

Growth: 9.3Profit: 6.5Value: 6.7Quality: 7.0
Piotroski: 5/9Altman Z: 0.75
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

APLTUndervalued (+55.2%)

Margin of Safety

+55.2%

Fair Value

$0.23

Current Price

$0.10

$0.13 discount

UndervaluedFair: $0.23Overvalued
ONCUndervalued (+80.1%)

Margin of Safety

+80.1%

Fair Value

$1767.21

Current Price

$346.51

$1420.70 discount

UndervaluedFair: $1767.21Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

APLT2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
720.0%10/10

Revenue surging 720.0% year-over-year

Debt/EquityHealth
-4.4610/10

Conservative balance sheet, low leverage

ONC4 strengths · Avg: 8.8/10
EPS GrowthGrowth
166.7%10/10

Earnings expanding 166.7% YoY

Debt/EquityHealth
0.229/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.778/10

Growing faster than its price suggests

Revenue GrowthGrowth
29.6%8/10

Revenue surging 29.6% year-over-year

Areas to Watch

APLT4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$14.86M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

ONC2 concerns · Avg: 2.0/10
P/E RatioValuation
64.1x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
0.752/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : APLT

The strongest argument for APLT centers on Revenue Growth, Debt/Equity. Revenue growth of 720.0% demonstrates continued momentum.

Bull Case : ONC

The strongest argument for ONC centers on EPS Growth, Debt/Equity, PEG Ratio. Revenue growth of 29.6% demonstrates continued momentum. PEG of 0.77 suggests the stock is reasonably priced for its growth.

Bear Case : APLT

The primary concerns for APLT are EPS Growth, Market Cap, Profit Margin.

Bear Case : ONC

The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 64.1x leaves little room for execution misses.

Key Dynamics to Monitor

APLT profiles as a hypergrowth stock while ONC is a growth play — different risk/reward profiles.

APLT carries more volatility with a beta of 2.08 — expect wider price swings.

APLT is growing revenue faster at 720.0% — sustainability is the question.

ONC generates stronger free cash flow (596M), providing more financial flexibility.

Bottom Line

ONC scores higher overall (64/100 vs 27/100) and 29.6% revenue growth. APLT offers better value entry with a 55.2% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Applied Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to combat cardiovascular disease, galactosemia, and diabetes complications. The company is headquartered in New York, New York.

Visit Website →

BeiGene, Ltd.

HEALTHCARE · BIOTECHNOLOGY · USA

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.

Visit Website →

Want to dig deeper into these stocks?